Physician profile
Michael Mcmanus
NPI 1609085612
$6,179.63
in general payments reported to CMS, 2019-2025
36 companies · $62.23 in 2025
The $62.23 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $369 · 2021: $1,161 · 2022: $1,810 · 2023: $1,839 · 2024: $305 · 2025: $62.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $868.66 | 2021-2024 | Urolift |
| Isoray, INC | $635.42 | 2023-2024 | Brachytherapy Source |
| Medtronic, INC. | $416.61 | 2021-2023 | Interstim |
| Astellas Pharma US INC | $406.97 | 2019-2024 | Xtandi, Veozah |
| Allergan, INC. | $381.27 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $317.43 | 2019-2024 | Provenge |
| Endo Pharmaceuticals INC. | $293.99 | 2019-2024 | Aveed, Xiaflex, Edex |
| Pfizer INC. | $282.41 | 2019-2023 | |
| Procept Biorobotics Corporation | $273.59 | 2022-2025 | |
| Antares Pharma, INC. | $223.84 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Amgen INC. | $218.09 | 2019-2023 | Prolia |
| Abbvie INC. | $217.05 | 2019-2024 | |
| Janssen Biotech, INC. | $170.92 | 2019-2022 | |
| Blue Earth Diagnostics | $131.26 | 2019-2022 | |
| Intuitive Surgical, INC. | $111.52 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $109.79 | 2021-2022 | |
| 180 Medical, INC. | $109.27 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $95.78 | 2022-2023 | Lynparza |
| Urogen Pharma, INC. | $91.40 | 2020-2023 | Jelmyto |
| Angiodynamics, INC. | $89.53 | 2021-2022 | |
| Myovant Sciences INC. | $77.12 | 2021-2022 | |
| Coloplast Corp | $70.45 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $70.23 | 2023 | Orgovyx, Gemtesa |
| Olympus America INC. | $55.23 | 2020-2022 | |
| Medtronic USA, INC. | $53.25 | 2019-2020 | |
| Tolmar, INC. | $52.56 | 2023 | |
| Merck Sharp & Dohme LLC | $48.02 | 2021-2023 | Lynparza |
| C. R. Bard, INC. & Subsidiaries | $47.95 | 2021 | |
| Accord Healthcare, INC. | $44.15 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.94 | 2021-2022 | |
| Halozyme INC | $34.85 | 2023 | |
| Boston Scientific Corporation | $34.69 | 2019 | |
| Medtronic Vascular, INC. | $33.17 | 2019 | |
| Urovant Sciences INC | $26.49 | 2021 | |
| Foundation Medicine, INC. | $25.37 | 2020-2021 | |
| Endo USA, INC. | $24.36 | 2025 | Aveed, Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.